2500: Possible accommodation in a bilateral transhumeral transplant [sessiontypeP]
P. Cavadas, A. Thione
{"title":"2500: Possible accommodation in a bilateral transhumeral transplant [sessiontypeP]","authors":"P. Cavadas, A. Thione","doi":"10.1080/23723505.2016.1234217","DOIUrl":null,"url":null,"abstract":"2500: Possible accommodation in a bilateral transhumeral transplant [sessiontypeP] Pedro C. Cavadas, MD, PhD and Alessandro Thione, MD, PhD Clinica Cavadas, Valencia, Spain Immunological accommodation is a described intriguing mechanism by which DSA are present in a transplanted patient without evidence of organ damage. It has been described in solid organ transplantations but, to the best of the authors knowledge, not in VCA. A young male patient with bilateral transhumeral amputation was transplanted in 2008. The clinical and immunological evolution was relatively uneventful for 4 years, with excellent function. In 2012 the patient tested positive for DSA (anti DQ7, DQ8, DQ9) complement-fixing, at high MFI (16000), without clinical or histological evidence of rejection. The patient was treated with Bortezomib, 4 cycles, without clearance of the DSA. The MFI decreased to around 4000 and have remained like this ever since. Given the complete absence of clinical or pathological evidence of rejection, and the risk of complications with escalating depleting treatments, the decision of not giving further treatment was taken. Four years after the first positive DSA test, the clinical and pathological findings are normal, without evidence of organ damage. If this case constitutes a true accommodation or just an inconspicuous impending rejection will require longer follow-up. CONTACT Pedro C. Cavadas, MD, PhD pcavadas@telefonica.net © 2016 Pedro C. Cavadas and Alessandro Thione. Published with license by Taylor & Francis. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. VASCULARIZED COMPOSITE ALLOTRANSPLANTATION 2016, VOL. 3, NOS. 1–2, 34 http://dx.doi.org/10.1080/23723505.2016.1234217","PeriodicalId":372758,"journal":{"name":"Vascularized Composite Allotransplantation","volume":"40 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascularized Composite Allotransplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23723505.2016.1234217","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
2500: Possible accommodation in a bilateral transhumeral transplant [sessiontypeP] Pedro C. Cavadas, MD, PhD and Alessandro Thione, MD, PhD Clinica Cavadas, Valencia, Spain Immunological accommodation is a described intriguing mechanism by which DSA are present in a transplanted patient without evidence of organ damage. It has been described in solid organ transplantations but, to the best of the authors knowledge, not in VCA. A young male patient with bilateral transhumeral amputation was transplanted in 2008. The clinical and immunological evolution was relatively uneventful for 4 years, with excellent function. In 2012 the patient tested positive for DSA (anti DQ7, DQ8, DQ9) complement-fixing, at high MFI (16000), without clinical or histological evidence of rejection. The patient was treated with Bortezomib, 4 cycles, without clearance of the DSA. The MFI decreased to around 4000 and have remained like this ever since. Given the complete absence of clinical or pathological evidence of rejection, and the risk of complications with escalating depleting treatments, the decision of not giving further treatment was taken. Four years after the first positive DSA test, the clinical and pathological findings are normal, without evidence of organ damage. If this case constitutes a true accommodation or just an inconspicuous impending rejection will require longer follow-up. CONTACT Pedro C. Cavadas, MD, PhD pcavadas@telefonica.net © 2016 Pedro C. Cavadas and Alessandro Thione. Published with license by Taylor & Francis. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. VASCULARIZED COMPOSITE ALLOTRANSPLANTATION 2016, VOL. 3, NOS. 1–2, 34 http://dx.doi.org/10.1080/23723505.2016.1234217
2500:双侧肱骨移植的可能适应[sessiontypeP]
Pedro C. Cavadas, MD, PhD和Alessandro Thione, MD, PhD, Clinica Cavadas, Valencia, Spain,免疫调节是一种有趣的机制,通过这种机制,移植患者在没有器官损伤证据的情况下存在DSA。它已经在实体器官移植中描述过,但据作者所知,没有在VCA中描述过。一例年轻男性患者于2008年接受双侧肱骨截骨手术。4年临床和免疫学进展相对平稳,功能良好。2012年,该患者在高MFI(16000)下检测DSA(抗DQ7、DQ8、DQ9)补体固定阳性,无临床或组织学排斥证据。患者接受硼替佐米治疗,4个周期,无DSA清除。MFI下降到4000左右,并一直保持这种状态。考虑到完全没有临床或病理排斥反应的证据,以及不断升级的消耗性治疗的并发症风险,我们决定不再进行进一步治疗。第一次DSA检测阳性四年后,临床和病理结果正常,无器官损伤的证据。如果这种情况构成了真正的适应,或者只是一个不起眼的即将发生的拒绝,将需要更长时间的随访。Pedro C. Cavadas, MD, PhD pcavadas@telefonica.net©2016 Pedro C. Cavadas and Alessandro Thione。由Taylor & Francis授权出版。这是一篇在知识共享署名-非商业许可(http://creativecommons.org/licenses/by-nc/3.0/)条款下发布的开放获取文章,该许可允许在任何媒体上不受限制的非商业使用、分发和复制,前提是正确引用原始作品。指定作者的精神权利得到了维护。血管化复合异体移植,2016,VOL. 3, no . 1-2, 34 http://dx.doi.org/10.1080/23723505.2016.1234217
本文章由计算机程序翻译,如有差异,请以英文原文为准。